This week we had Eyes On recent FDA actions including the approval of AstraZeneca’s first fixed-duration BTK inhibitor regimen for first-line CLL/SLL; A warning letter for Johnson & Johnson concerning promotional claims for Tremfya; and Moderna's resolution of the refusal-to-file dispute and a PDUFA for it's flu vaccine decision in 2026.

At PharmaTell we keep Eyes on Strategic moves within the market. This week we're diving into Merck & Co's plans for the future. With the upcoming patent expiry for Keytruda, they are planning to bolster their pipeline with new products and indications via internal development and M&A.

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and